Your browser is no longer supported. Please, upgrade your browser.
Settings
FGEN [NASD]
FibroGen, Inc.
Index- P/E- EPS (ttm)-2.13 Insider Own1.30% Shs Outstand91.17M Perf Week-9.36%
Market Cap1.90B Forward P/E- EPS next Y-2.22 Insider Trans-3.81% Shs Float83.64M Perf Month7.55%
Income-189.30M PEG- EPS next Q-0.87 Inst Own79.50% Short Float9.87% Perf Quarter-61.29%
Sales176.30M P/S10.78 EPS this Y-137.10% Inst Trans0.11% Short Ratio4.83 Perf Half Y-51.67%
Book/sh4.63 P/B4.37 EPS next Y-52.10% ROA-23.10% Target Price- Perf Year-44.45%
Cash/sh7.31 P/C2.77 EPS next 5Y- ROE-43.80% 52W Range18.12 - 57.21 Perf YTD-45.46%
Dividend- P/FCF24.49 EPS past 5Y-8.20% ROI-40.20% 52W High-64.64% Beta1.02
Dividend %- Quick Ratio4.50 Sales past 5Y-0.50% Gross Margin95.00% 52W Low11.64% ATR1.57
Employees599 Current Ratio4.60 Sales Q/Q712.50% Oper. Margin- RSI (14)33.82 Volatility5.48% 5.42%
OptionableYes Debt/Eq0.13 EPS Q/Q43.20% Profit Margin- Rel Volume0.40 Prev Close20.64
ShortableYes LT Debt/Eq0.10 EarningsMay 10 AMC Payout- Avg Volume1.71M Price20.23
Recom2.50 SMA20-2.20% SMA50-30.11% SMA200-49.41% Volume686,278 Change-1.99%
Apr-07-21Downgrade Mizuho Buy → Neutral $72 → $29
Apr-07-21Downgrade H.C. Wainwright Buy → Neutral
Mar-31-21Upgrade BofA Securities Neutral → Buy $47
Mar-02-21Downgrade Jefferies Buy → Hold $75 → $45
Feb-01-21Initiated H.C. Wainwright Buy $58
Oct-26-20Initiated Raymond James Underperform
Jul-10-20Resumed Stifel Buy $71
May-01-20Initiated Cowen Market Perform $40
Apr-27-20Initiated BofA/Merrill Neutral $45
May-29-19Resumed Goldman Neutral
May-10-19Downgrade William Blair Outperform → Mkt Perform
Apr-12-19Initiated Piper Jaffray Neutral $65
Feb-11-19Resumed Stifel Buy $71
Dec-19-18Upgrade Citigroup Neutral → Buy
Aug-08-17Reiterated Stifel Buy $38 → $80
Aug-08-17Reiterated Leerink Partners Outperform $52 → $82
Jul-21-17Downgrade Goldman Buy → Neutral
Jul-11-17Initiated Jefferies Buy
Feb-11-16Upgrade Credit Suisse Neutral → Outperform $40
Jan-21-16Initiated Credit Suisse Neutral
May-08-21 01:54PM  
01:15PM  
11:00AM  
08:06AM  
May-07-21 10:40PM  
07:05PM  
06:47PM  
05:55PM  
05:00PM  
04:30PM  
03:15PM  
12:20PM  
12:00PM  
11:20AM  
10:15AM  
09:30AM  
08:45AM  
05:40AM  
May-06-21 10:50PM  
09:31PM  
07:20PM  
04:50PM  
11:25AM  
11:06AM  
10:50AM  
09:30AM  
09:00AM  
06:32AM  
May-05-21 11:01PM  
10:12PM  
07:15PM  
06:18PM  
05:16PM  
03:29PM  
01:45PM  
01:40PM  
01:24PM  
11:55AM  
11:30AM  
11:15AM  
11:15AM  
10:39AM  
06:10AM  
May-04-21 10:50PM  
09:11PM  
07:02PM  
06:01PM  
04:37PM  
03:00PM  
02:00PM  
12:30PM  
11:00AM  
10:51AM  
10:04AM  
09:30AM  
06:30AM  
May-03-21 11:03PM  
08:29PM  
06:59PM  
06:34PM  
05:09PM  
02:45PM  
02:30PM  
02:00PM  
01:20PM  
12:40PM  
11:10AM  
11:00AM  
10:52AM  
10:30AM  
07:00AM  
06:04AM  
May-01-21 03:36PM  
01:28PM  
08:31AM  
Apr-30-21 10:50PM  
04:50PM  
02:15PM  
12:45PM  
11:37AM  
10:05AM  
09:41AM  
09:00AM  
06:30AM  
01:00AM  
Apr-29-21 07:32PM  
05:59PM  
05:29PM  
05:02PM  
03:07PM  
02:05PM  
01:31PM  
01:00PM  
12:15PM  
12:00PM  
11:35AM  
10:40AM  
10:14AM  
10:00AM  
06:30AM  
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KEARNS THOMAS F JRDirectorMar 11Option Exercise3.5018,00063,000166,164Mar 15 06:22 PM
KEARNS THOMAS F JRDirectorMar 11Sale35.0218,000630,360148,164Mar 15 06:22 PM
Kurkijarvi KaleviDirectorFeb 17Option Exercise28.656,000171,90039,100Feb 19 07:10 PM
Kurkijarvi KaleviDirectorFeb 17Sale52.406,000314,38333,100Feb 19 07:10 PM
Kurkijarvi KaleviDirectorJan 19Option Exercise19.056,000114,30039,100Jan 21 07:24 PM
Kurkijarvi KaleviDirectorJan 19Sale43.386,000260,28033,100Jan 21 07:24 PM
Kurkijarvi KaleviDirectorJan 14Option Exercise19.055,999114,28139,099Jan 15 08:02 PM
Kurkijarvi KaleviDirectorJan 14Sale40.045,999240,20033,100Jan 15 08:02 PM
Schoeneck James ADirectorJan 04Option Exercise9.786,00058,65015,400Jan 06 07:08 PM
Kurkijarvi KaleviDirectorDec 28Option Exercise18.346,001110,05939,101Dec 30 06:07 PM
Kurkijarvi KaleviDirectorDec 28Sale40.406,001242,45533,100Dec 30 06:07 PM
Yu K PeonyChief Medical OfficerDec 16Sale41.613,350139,394192,292Dec 17 07:06 PM
Cotroneo PatSVP, Finance and CFODec 15Sale43.603,068133,765266,144Dec 17 07:04 PM
Kouchakji EliasSVP, Clinical Dev, Drug SafetyNov 17Option Exercise14.577,082103,220134,495Nov 19 04:52 PM
Yu K PeonyChief Medical OfficerSep 16Sale44.013,351147,478198,934Sep 18 05:19 PM
Cotroneo PatSVP, Finance and CFOSep 15Sale43.633,070133,944272,226Sep 17 06:03 PM
Cotroneo PatSVP, Finance and CFOSep 03Option Exercise23.3015,004349,582293,314Sep 04 04:30 PM
Yu K PeonyChief Medical OfficerSep 03Option Exercise18.0010,000180,000215,576Sep 04 04:33 PM
Yu K PeonyChief Medical OfficerSep 03Sale50.8910,000508,900205,576Sep 04 04:33 PM
Cotroneo PatSVP, Finance and CFOSep 03Sale50.9115,004763,854278,310Sep 04 04:30 PM
Schoeneck James ADirectorAug 20Option Exercise5.956,00035,70015,400Aug 21 05:58 PM
Cotroneo PatSVP, Finance and CFOAug 11Option Exercise18.727,250135,712278,310Aug 11 04:34 PM
Cotroneo PatSVP, Finance and CFOAug 07Option Exercise19.3922,554437,322293,614Aug 11 04:34 PM
Cotroneo PatSVP, Finance and CFOAug 07Sale48.0022,5541,082,592271,060Aug 11 04:34 PM
Yu K PeonyChief Medical OfficerJul 24Sale42.353,351141,915205,576Jul 28 07:33 PM
Cotroneo PatSVP, Finance and CFOJun 16Sale39.683,928155,863271,060Jun 18 06:35 PM
Conterno Enrique AChief Executive OfficerJun 11Buy35.2819,800698,59927,800Jun 12 06:59 AM
Conterno Enrique AChief Executive OfficerJun 10Buy36.298,000290,2828,000Jun 12 06:59 AM
Rosenkranz Roberto PedroDirectorJun 09Option Exercise23.8524,000572,40096,100Jun 11 09:22 PM